Demystifying New Evidence for COPD Management Best Practices for Primary Care

Fernando J. Martinez, MD, MS

This activity is jointly provided by Global Education Group and Integritas Communications.


This activity is supported by an independent educational grant from AstraZeneca.


Fernando J. Martinez, MD, MS
Chief, Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York - Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Target Audience

The educational design of this activity addresses the needs of primary care providers, including physicians, nurse practitioners, and physician assistants, involved in the care of patients with chronic obstructive pulmonary disease (COPD).

Program Overview

As their lung function progressively declines, patients with COPD are at increased risk for exacerbations and hospitalizations—major drivers of morbidity, mortality, and overall medical costs associated with the disease.1,2 Additionally, the emergence of the COVID-19 pandemic has placed patients with COPD at even greater risk for poor outcomes, while confounding frontline primary care clinicians as to how to best manage this at-risk patient population.3,4 In this Point-of-Care 101 (POC101) educational program, a renowned expert in COPD will review best practices in evaluating and managing patients with moderate to very severe COPD, particularly within the present COVID-19 landscape. Faculty will also highlight recently released clinical data surrounding available and emerging maintenance therapies for this at-risk patient population. With the ultimate goal of improving patient outcomes, this program provides recommendations on how the latest evidence and updated COPD guidelines can best be utilized to tailor individualized COPD management strategies within today’s primary care practice.


  1. Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update—highlights for primary care. Can Respir J. 2008;15 (suppl A):1A-8A.
  2. Ekstrom M, Sundh J, Larsson K. Patient reported outcome measures in chronic obstructive pulmonary disease: Which to use? Expert Rev Respir Med. 2016;10(3):351-362.
  3. Guan WJ, Liang WH, Zhao Y, et al, for the China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.
  4. Tal-Singer R, Crapo JD. COPD at the time of COVID-19: a COPD Foundation perspective. Chronic Obstr Pulm Dis. 2020;7(2):73-75.

Educational Objectives

After completing this activity, the participant should be better able to:

  1. Discuss the recently published data from national conferences and peer-reviewed journals on the ongoing treatment of patients with COPD
  2. Tailor maintenance regimens for patients with COPD to reflect disease severity, exacerbation risks, comorbidities, and the latest clinical evidence

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.50 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Term of Offering

This activity was released on July 31, 2020 and is valid for one year. Requests for credit must be made no later than July 31, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 80% or better on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Fernando J. Martinez, MD, MS: Consultant/Independent Contractor: AstraZeneca, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, IQVIA, ProterixBio, Inc., Raziel Therapeutics, Sanofi/Regeneron, Teva Pharmaceutical Industries Ltd., twoXAR Pharmaceuticals, Verona Pharma plc. Grant/Research Support: Afferent Pharmaceuticals/Merck, AstraZeneca, Bayer AG, Boehringer Ingelheim, Biogen Inc., GlaxoSmithKline, Promedior/Roche, Respivant Sciences, Inc., Veracyte, Inc. Speaker’s Bureau: CME Outfitters, Integritas Communications, MedScape, Methodist Hospital, Haymarket Media, Inc., PeerView, UpToDate, Vindico Medical Education, WebMD. Data Safety Monitoring Board: Biogen Inc., Boehringer Ingelheim, Genentech, Inc., GlaxoSmithKline

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 07/31/2021

type POC101